Items Tagged ‘perjeta’

March 26, 2018

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer


CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among […]

View full entry

Tags: Breast Cancer, HER-2, neu positive, News, perjeta, pertuzumab